The use of developmental therapeutics has expanded the treatment of gynecologic cancers beyond traditional chemotherapy. Since options can now be biomarker-driven, sequencing of agents is key to ...

Texas A&M scientists have unlocked new potential for astatine-211, a rare and short-lived element, as a highly precise cancer-fighting isotope. Its alpha emissions destroy tumor cells while sparing ...

One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer ...

"We’re in an exciting time for clinical research related to endometrial cancer, with a multitude of novel therapies being developed and in clinical trials right now. We’re making significant ...

Early-stage gynecologic cancer is confined to its original site and often treatable; diagnosis, surgery, and new therapies improve outcomes. Your diagnosis of an early-stage (Stage 1) gynecologic ...